Scottish digital transformation consultancy Storm ID has developed a new digital solution to help predict respiratory failure in COVID-19 patients. The solution is being trialled in respiratory failure patients, following funding from Scottish Government Chief Scientist Office.
Our Lenus Health Platform supports remote patient monitoring and so it was only natural for us to look at how this could be made available to COVID-19 patients. The CARP solution will provide a basis for exploring how the NHS can use this innovative sensor to proactively monitor patients.
Paul McGinness, Director at Storm ID
CARP will provide us with critical, real-time capability to identify and triage COVID-19 patients at risk of deterioration. This will greatly assist clinicians as patient numbers increase.
Dr Chris Carlin, Consultant Physician at NHS Greater Glasgow and Clyde
The CARP trial has allowed unique insights into the effects of COVID-19 and the data analysis methods developed will enhance the use of Altair Medical’s technology in a range of respiratory conditions. This would not have been possible without the Lenus Health Platform – it provides a pivotal link in safely and securely maximising the real-world utility of biosensor data.
Dr Bruce Henderson, CEO of Altair Medical
About Storm ID and Lenus Health
About Altair Medical
About NHS Greater Glasgow and Clyde
Director at Storm ID